GEOVAX LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-09-30 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-06-30 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-03-31 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2012-12-31 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares S-1 · filed 2026-09-17 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-27 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-29 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-23 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-09 | |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2013-11-12 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | 0.00 shares derived: sum of 4 quarters · filed 2013-08-12 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-01 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | 0.00 shares 10-K · filed 2013-03-18 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |